Stock Market News3 weeks PFE’s Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS Zacks
Pfizer’s late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS with statistical significance.
XPfizer’s late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS with statistical significance.
X